Lexicon Pharma (LXRX) Tops Q3 EPS by 14c

November 1, 2016 8:15 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.35), $0.14 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $27.7 million versus the consensus estimate of $9.68 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment